S&P 500
7,457.20
+0.06%
Dow Jones
52,280.10
-0.03%
Nasdaq 100
29,846.10
+0.15%
Russell 2000
3,010.12
+0.03%
FTSE 100
10,529.00
-0.11%
Nikkei 225
70,254.80
-0.57%
Jazz Pharmaceuticals

Jazz Pharmaceuticals (JAZZ) Q3 2025 Earnings

Reported Nov 5, 2025 at 4:07 PM ET · SEC Source

Q3 25 EPS

$8.13

BEAT +38.97%

Est. $5.85

Q3 25 Revenue

$1.13B

BEAT +1.58%

Est. $1.11B

vs S&P Since Q3 25

+59.3%

BEATING MARKET

JAZZ +69.8% vs S&P +10.5%

Market Reaction

Did JAZZ Beat Earnings? Q3 2025 Results

Jazz Pharmaceuticals delivered a standout third quarter, posting adjusted earnings of $8.13 per diluted share against a consensus estimate of $5.85, a beat of nearly 39%, while revenue of $1.13 billion edged past expectations by 1.58% and climbed 6.7… Read more Jazz Pharmaceuticals delivered a standout third quarter, posting adjusted earnings of $8.13 per diluted share against a consensus estimate of $5.85, a beat of nearly 39%, while revenue of $1.13 billion edged past expectations by 1.58% and climbed 6.7% year over year. The quarter marked a record revenue performance for the company, with its neuroscience franchise supplying most of the momentum; Xywav grew 11% to $431.40 million and Epidiolex surged 20% to $302.60 million on strong volume and favorable pricing dynamics. Two FDA approvals added strategic depth, including the accelerated green light for Modeyso in a rare brain tumor indication, which generated $11.00 million in its initial partial quarter on shelves. GAAP results were weighed down by a combined $151.50 million in litigation settlements and a $42.50 million acquired IPR&D charge, though a $205.90 million tax benefit softened the blow. Looking ahead, management raised its full-year adjusted EPS guidance to $7.65 to $8.45, even as some observers note the stock's below-industry valuation reflects lingering questions about longer-term revenue trajectory.

Key Takeaways

  • • Epidiolex 20% net product sales growth driven by 10% volume increase and lower U.S. gross-to-net deductions
  • • Xywav 11% net product sales growth with approximately 450 net patient adds in the quarter
  • • Modeyso launched in August 2025 with strong initial uptake generating $11.0 million in first partial quarter
  • • Total neuroscience revenue increased 9% to $827.4 million including royalties
  • • Non-GAAP adjusted gross margin of 92.2%
  • • $205.9 million income tax benefit from recognition of Chimerix-acquired U.S. deferred tax assets
24/7 Wall St

JAZZ YoY Financials

Q3 2025 vs Q3 2024, source: SEC Filings

24/7 Wall St

JAZZ Revenue by Segment

With YoY comparisons, source: SEC Filings

Q2 25 Q1 26

“Achieving the highest revenue quarter in Jazz's history speaks to the strength of our diversified portfolio and the outstanding performance of our team. We were pleased to once again deliver solid execution across our sleep, epilepsy and oncology portfolios, led by double-digit percentage growth from Epidiolex and Xywav.”

— Renee Gala, Q3 2025 Earnings Press Release

Back to JAZZ Stock Page